Jade Biosciences is a clinical-stage biotechnology company working to develop new therapies for autoimmune diseases. Its lead program, JADE101, is an antibody designed to block APRIL, a cytokine involved in immune regulation, and is being developed for immunoglobulin A nephropathy (IgAN). The company is building its pipeline with discovery-stage assets licensed from Paragon Therapeutics and advancing clinical programs intended to address significant unmet needs in autoimmune care.
Lead clinical operations for Jade Biosciences’ autoimmune disease therapies across Phase 1–3 trials. Coordinate CROs, budgets, vendors, sites, compliance, and study delivery.